Improving monoclonal antibodies for cancer therapy

Continuous cultures of fused cells secreting antibody of predefined specificity

1975 • 17,037 citations

Complement

2001 • 2,792 citations

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

2000 • 2,694 citations

Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis

1989 • 1,739 citations

Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity

2002 • 1,698 citations

Ligand-targeted therapeutics in anticancer therapy

2002 • 1,592 citations

F<scp>c</scp>RECEPTOR BIOLOGY

1997 • 1,219 citations

High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR

2001 • 1,108 citations

FcR γ chain deletion results in pleiotrophic effector cell defects

1994 • 967 citations

Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

1992 • 824 citations

Improving the efficacy of antibody-based cancer therapies

2001 • 821 citations

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

1999 • 751 citations

Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure.

1988 • 703 citations

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

2002 • 638 citations

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

2001 • 599 citations

Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.

1990 • 567 citations

Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.

1985 • 566 citations

Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20⁺B-Cell Non-Hodgkin's Lymphoma

1999 • 563 citations

Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates

1993 • 545 citations

Hybrid hybridomas and their use in immunohistochemistry

1983 • 497 citations

Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins

2002 • 468 citations

Efficient construction of a large nonimmune phage antibody library: The production of high-affinity human single-chain antibodies to protein antigens

1998 • 437 citations

Design and Use of a Phage Display Library

1998 • 423 citations

Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc

2000 • 416 citations

Radioimmunotherapy with alpha-emitting nuclides

1998 • 398 citations

The IgG Fc receptor family

1998 • 398 citations

Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier.

1992 • 397 citations

Engineered antibodies

2003 • 385 citations

Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site

1996 • 380 citations

A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.

1990 • 343 citations

A faster-acting and more potent form of tissue plasminogen activator.

1994 • 343 citations

Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.

1991 • 342 citations

Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.

1999 • 329 citations

Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.

1996 • 329 citations

Fc receptors are required in passive and active immunity to melanoma

1998 • 322 citations

Effect of glycosylation on antibody function: implications for genetic engineering

1997 • 311 citations

Fc RECEPTORS AND THEIR INTERACTIONS WITH IMMUNOGLOBULINS

1996 • 309 citations

Human Immune Respone to Monoclonal Antibodies

1994 • 297 citations

THE ROLE OF THE KIDNEY IN THE CATABOLISM OF BENCE JONES PROTEINS AND IMMUNOGLOBULIN FRAGMENTS

1967 • 295 citations

Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using Affinity-driven Selection

1996 • 295 citations

Engineered Antibodies with Increased Activity to Recruit Complement

2001 • 285 citations

Vascular leak syndrome: a side effect of immunotherapy

1997 • 260 citations

Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature

2002 • 258 citations

Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv.

1993 • 257 citations

Mechanism of action of trastuzumab and scientific update

2001 • 250 citations

Therapeutic inhibition of the complement system.

1998 • 242 citations

Increasing the serum persistence of an IgG fragment by random mutagenesis

1997 • 236 citations

Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.

1998 • 234 citations

FcRn: the MHC class I-related receptor that is more than an IgG transporter

1997 • 218 citations

(6-Maleimidocaproyl)hydrazone of doxorubicin. A new derivative for the preparation of immunoconjugates of doxorubicin

1993 • 218 citations

Natural and designer binding sites made by phage display technology

2000 • 216 citations

Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains.

1996 • 214 citations

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

1998 • 209 citations

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.

2000 • 208 citations

Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome

1999 • 199 citations

The use of hybrid hybridomas to target human cytotoxic T lymphocytes

1987 • 199 citations

Human Macrophages Armed with Murine Immunoglobulin G2a Antibodies to Tumors Destroy Human Cancer Cells

1983 • 199 citations

Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens.

1988 • 194 citations

Monoclonal Antibody Therapy for Cancer

2003 • 192 citations

Overview of Antibody Phage-Display Technology and Its Applications

2003 • 184 citations

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.

1995 • 184 citations

Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions

1995 • 177 citations

Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugates

2001 • 174 citations

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.

1992 • 173 citations

Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer.

1989 • 167 citations

Bispecific antibodies in cancer therapy

1999 • 166 citations

Bispecific human IgG by design

2001 • 163 citations

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

2002 • 158 citations

Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives.

1995 • 158 citations

Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor

1995 • 148 citations

Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

1995 • 138 citations

Pretargeted Radioimmunotherapy (PRIT™) for Treatment of Non-Hodgkin's Lymphoma (NHL): Initial Phase I/II Study Results

2000 • 137 citations

Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice

2003 • 134 citations

Antibody-Targeted Immunotherapy for Treatment of Malignancy

2001 • 129 citations

Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer.

1991 • 124 citations

Tumour therapy with radionuclides: assessment of progress and problems

2003 • 118 citations

Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis

1998 • 115 citations

Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.

2002 • 114 citations

Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.

2000 • 113 citations

Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.

1999 • 113 citations

Prolonged Circulating Lives of Single-Chain Fv Proteins Conjugated with Polyethylene Glycol: A Comparison of Conjugation Chemistries and Compounds

1999 • 112 citations

Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.

1992 • 111 citations

Potent Antithrombin Activity and Delayed Clearance From the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin

1997 • 109 citations

Immunocytokines

1998 • 99 citations

Tumor Targeting of Mono-, Di-, and Tetravalent Anti-p185HER-2 Miniantibodies Multimerized by Self-associating Peptides

2001 • 94 citations

Engineering Antibodies for Therapy

2002 • 92 citations

Monoclonal antibody drug conjugates in the treatment of cancer

1999 • 88 citations

Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys

1999 • 87 citations

Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes.

1985 • 84 citations

Delivery of the α-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules

2000 • 79 citations

In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: A strategy to increase tumor radiolocalization

1988 • 78 citations

Catalytic activity of anin vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein

2000 • 65 citations

Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.

2001 • 65 citations

Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors.

1999 • 64 citations

Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide.

1995 • 62 citations

Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.

1997 • 60 citations

Bispecific antibodies targeting cancer cells

2002 • 57 citations

Tumor‐targeting properties of antibody–vascular endothelial growth factor fusion proteins

2002 • 57 citations

Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12

1999 • 54 citations

Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis.

2002 • 54 citations

Pretargeting for Cancer Radioimmunotherapy with Bispecific Antibodies: Role of the Bispecific Antibody's Valency for the Tumor Target Antigen

2002 • 49 citations

Reduction of the Nonspecific Animal Toxicity of Anti-Tac(Fv)-PE38 by Mutations in the Framework Regions of the Fv Which Lower the Isoelectric Point

1999 • 49 citations

Bivalent Hapten-Bearing Peptides Designed for Iodine-131 Pretargeted Radioimmunotherapy

1997 • 46 citations

Synergy between vascular targeting agents and antibody-directed therapy

2002 • 44 citations

A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics

2002 • 44 citations

Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.

1993 • 44 citations

Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment.

1998 • 43 citations

Radioimmunotherapy of Solid Tumors: A Review "Of Mice and Men"

1997 • 41 citations

Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis

1999 • 40 citations

Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.

1999 • 38 citations

Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.

2001 • 36 citations

Monoclonal antibody homodimers: enhanced antitumor activity in nude mice.

1993 • 35 citations

Treatment of Malignancy with Unmodified Antibody

1987 • 34 citations

N-Succinimidyl 3-[¹³¹I]Iodo-4-phosphonomethylbenzoate ([¹³¹I]SIPMB), a Negatively Charged Substituent-Bearing Acylation Agent for the Radioiodination of Peptides and mAbs

2003 • 33 citations

The macroscopic and microscopic pharmacology of monoclonal antibodies

1992 • 32 citations

INTERFERENCE OF MACROPHAGES WITH IMMUNOTARGETING OF LIPOSOMES

2002 • 27 citations

Generation of Human Interferon Gamma and Tumor Necrosis Factor Alpha Chimeric TNT-3 Fusion Proteins

2002 • 27 citations

Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers.

1995 • 22 citations

New Anti-Cu-TETA and Anti-Y-DOTA Monoclonal Antibodies for Potential Use in the Pre-Targeted Delivery of Radiopharmaceuticals to Tumor

1998 • 22 citations

Preparation of a trivalent antigen-binding construct using polyoxime chemistry: improved biodistribution and potential for therapeutic application.

1996 • 22 citations

Cleavable Linkers to Enhance Selectivity of Antibody-Targeted Therapy of Cancer

2001 • 19 citations

Antitumor activity of L/1C2-4-desacetylvinblastine-3-carboxhydrazide immunoconjugate in xenografts.

1990 • 15 citations

Development and Effects of Immunoliposomes Carrying an Antisense Oligonucleotide Against DHFR RNA and Directed Toward Human Breast Cancer Cells Overexpressing HER2

2002 • 9 citations

Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys This article is a US Government work and, as such, is in the public domain in the United States of America.

1999 • 6 citations